Latest Healthcare News

Little Green Pharma has issued a supplementary scheme booklet updating Cannatrek shareholders on the acquisition progress, including a revised timetable and the termination of a planned sale and leaseback of its WA production facility. Both companies’ boards continue to recommend the scheme, supported by an independent expert’s positive assessment.

AdAlta’s BZDS1901 CAR-T therapy shows remarkable tumour shrinkage and complete responses in advanced mesothelioma patients, doubling expected outcomes and paving the way for higher dosing and expanded trials.

AVITA Medical has lodged a new $200 million shelf registration with the SEC, renewing its capacity to issue various securities in the US market. While no immediate capital raising is planned, this move preserves the company’s financial agility for future growth opportunities.

Enlitic has landed a US$1.2 million contract to migrate and standardise millions of medical imaging records for Parkland Health, marking its third major US healthcare win this month.

Actinogen Medical has initiated the open-label extension of its XanaMIA Alzheimer’s trial, offering all participants active Xanamem treatment for up to 25 months to gather long-term safety and efficacy data ahead of final trial results.

Bioxyne Ltd has secured a manufacturing agreement with global cannabis giant Aurora Cannabis, marking a major step in its international expansion of pharmaceutical-grade medicinal cannabis products.

Pro Medicus Limited has announced an on-market buy-back program targeting up to 10% of its ordinary shares, aiming to return capital to shareholders without requiring approval.

Racura Oncology has enrolled the first patient in its Phase 1 HARNESS-1 trial, testing RC220 alongside osimertinib to tackle resistance in EGFR-mutant non-small cell lung cancer. This milestone sets the stage for a multi-centre study aiming to improve treatment outcomes.

Optiscan Imaging Ltd has taken a significant step towards commercialising its InSpecta® veterinary imaging device in the US by submitting a regulatory dossier to the FDA. This milestone not only initiates formal review but also sets the stage for broader clinical adoption and future device approvals.

Firebrick Pharma has successfully secured $1.5 million through a strategic placement, positioning itself to accelerate business development and launch new products in key markets.

Cleo Diagnostics has completed blood sample collection for its pivotal U.S. clinical trial, advancing its Pre-Surgical Ovarian Cancer Test closer to FDA submission.

Cyclopharm Limited is rapidly expanding its Technegas® lung imaging technology across the US, securing new contracts and advancing clinical guideline recognition that could boost adoption.